For each citation that was shared on social media (LinkedIn, Facebook, or Twitter) with the “@GenScript” tag, the author will be rewarded with a $10 Amazon gift card or 2,000 GS points.

Reduced DNAJC3 Expression Affects Protein Translocation across the ER Membrane and Attenuates the Down-Modulating Effect of the Translocation Inhibitor Cyclotriazadisulfonamide

Int J Mol Sci. 2022-01; 
Eva Pauwels, Becky Provinciael, Anita Camps, Enno Hartmann, Kurt Vermeire
Products/Services Used Details Operation
Protein and Antibody Isolation … Western blot and flow cytometry antibodies were purchased from (i) Genscript (Piscataway, NJ, USA): anti-V5 (cat #A01724); (ii) BD Biosciences (Allschwil, Switzerland): anti-clathrin (cat… Get A Quote

Abstract

One of the reported substrates for the endoplasmic reticulum (ER) translocation inhibitor cyclotriazadisulfonamide (CADA) is DNAJC3, a chaperone of the unfolded protein response during ER stress. In this study, we investigated the impact of altered DNAJC3 protein levels on the inhibitory activity of CADA. By comparing WT DNAJC3 with a CADA-resistant DNAJC3 mutant, we observed the enhanced sensitivity of human CD4, PTK7 and ERLEC1 for CADA when DNAJC3 was expressed at high levels. Combined treatment of CADA with a proteasome inhibitor resulted in synergistic inhibition of protein translocation and in the rescue of a small preprotein fraction, which presumably corresponds to the CADA affected protein fraction tha... More

Keywords

DNAJC3, ER quality control, Sec61 translocon, co-translational translocation, cyclotriazadisulfonamide, endoplasmic reticulum, preprotein, ribosome stalling, signal peptide